Kamada (KMDA)

[midastouch017]

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Kamada Ltd. (NASDAQ:KMDA).

According to the the latest analyst ratings which have been released, 1 brokers have issued a rating of “buy”, 0 brokers “outperform”, 0 brokers “hold”, 0 brokers “underperform” and 0 brokers “sell”.